RGEN Company Profile and Key Details

Q: Who are the executives of RGEN?

Mr. Ralf KuriyelSenior Vice President of R&DMs. Kimberly CornwellGlobal Head of Legal & Gen. CounselMr. Anthony J. HuntPres, Chief Executive Officer & DirectorMr. Stephen TingleyVice President & Head of Global SalesMr. Craig HarrisonSenior Vice President of AnalyticsMs. Christine GebskiSenior Vice President of Filtration & ChromatographyMs. Rachel GoodrichVice President of MarketingDr. Jaime M. Humara Ph.D.Senior Vice President of MarketingMr. Jon K. SnodgresChief Financial OfficerMr. Keith Lee RobinsonChief Information OfficerNeil WhitfieldVice President of SalesMs. Kimberly A. CornwellGen. CounselMr. James R. BylundChief Operating OfficerMr. Neil WhitfieldVice President of SalesMs. Sondra S. NewmanGlobal Head of Investor Relations

NASDAQ : RGEN

Repligen

$139.66

-6.45-4.41%

At Close 4:00 PM

68.57

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Repligen Corporation (RGEN) stock declined over -4.41%, trading at $139.66 on NASDAQ, down from the previous close of $146.11. The stock opened at $145.62, fluctuating between $138.52 and $147.16 in the recent session.

Stock Snapshot

146.11

Prev. Close

7.86B

Market Cap

138.515

Day Low

13966

P/E Ratio

0.01

EPS (TTM)

1.34

Cash Flow per Share

145.62

Open

56.29M

Number of Shares

147.1633

Day High

93.61%

Free Float in %

35.32

Book Value

765.8K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	145.62	147.16	138.51	139.66	772.94K
Feb 04, 2026	151.08	152.46	145.90	146.11	827.24K
Feb 03, 2026	152.40	160.88	145.01	150.23	1.06M
Feb 02, 2026	149.29	151.95	146.95	151.12	591.65K
Jan 30, 2026	156.32	157.44	148.84	149.37	889.17K
Jan 29, 2026	158.95	158.95	152.45	156.37	725.79K
Jan 28, 2026	161.36	162.98	157.77	160.05	438.79K
Jan 27, 2026	162.26	164.94	160.26	163.63	455.13K
Jan 26, 2026	163.41	166.78	161.76	163.34	496.26K
Jan 23, 2026	167.67	169.78	160.22	162.33	673.92K
Jan 22, 2026	170.81	174.87	166.40	167.93	540.34K
Jan 21, 2026	165.26	170.67	165.18	169.97	696.32K
Jan 20, 2026	159.54	165.60	157.29	163.33	476.83K
Jan 16, 2026	162.29	165.30	160.45	162.02	610.07K
Jan 15, 2026	162.06	165.03	158.80	161.69	741.23K
Jan 14, 2026	167.50	168.25	158.91	162.03	819.87K
Jan 13, 2026	170.04	172.51	160.57	167.31	999.67K
Jan 12, 2026	167.77	170.07	164.74	168.40	496.58K
Jan 09, 2026	167.49	169.56	164.29	166.82	396.11K
Jan 08, 2026	166.87	168.66	164.19	166.42	658.8K

Contact Details

Waltham, MA 02453

United States

https://www.repligen.com 781 250 0111

About Company

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Stock Peers

ISRG

-2.17-0.45%

Intuitive Surgical, Inc.$476.32 ATRI

0.26+0.06%

Atrion Corporation$459.92 ICUI

-0.34-0.23%

ICU Medical, Inc.$149.64 MASI

-1.29-0.94%

Masimo Corporation$135.33 LMAT

0.2+0.23%

LeMaitre Vascular, Inc.$86.99 COO

-0.82-1.01%

The Cooper Companies, Inc.$80.10 MMSI

0.26+0.33%

Merit Medical Systems, Inc.$79.63 HOLX

0.11+0.15%

Hologic, Inc.$74.70 UTMD

0.98+1.58%

Utah Medical Products, Inc.$62.86 MDLN

1.23+2.74%

Medline Inc.$46.20

Company Overview

Repligen Corporation (NASDAQ:RGEN) closed at $139.66 USD, losing -$6.45 (-4.41%) from the previous close of $146.11. The stock is currently mid-range between its 52-week high and low $102.97 and $175.77. With a market capitalization of about $7.86 billion, Repligen Corporation is classified as a mid-cap and shows market-like volatility (beta ~1.13). Key stats such as the average daily volume over the past year has been around 690.79 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, Repligen Corporation operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Olivier Loeillot, the company employs approximately 1,778 people and listed since April 29, 1986. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -12.66%, SMA50 -14.25%, SMA200 0.35%). The stock’s 14-day RSI is 25.73 (weak momentum), while the ATR of 7.19 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -20.54% below its high and over 35.64% above its low. Average 10-day trading volume of 720.44 thousand shares is in line with the 3-month average of 673.75 thousand, indicating normal recent market interest.

Valuation Metrics

Repligen Corporation trades at a P/E ratio of 4518.63, slightly above the S&P 500 average, with a price-to-sales ratio of 11.11 and a price-to-book ratio of 3.77 trading at moderately above to book value. The P/FCF stands at 73.86, also above market averages.

Dividend & Fair Value

Repligen Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $58.62. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 18.91% annually over the next five years. The latest quarter delivered EPS of $0.46. The next quarter is forecast at $0.44. Next year's EPS is expected at $3.96. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 4 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $205.00 to $130.00. The high target offers 46.79% upside. The low target suggests -6.92% downside. The mean target is $171.91. This offers 23.09% upside. Repligen Corporation earnings surprise history is a mixed track record. The quarter that ended October 28, 2025, missed forecasts by 9.52%. The prior quarter beat by -7.5%. Over the last six quarters, Apple has recorded several small beats. These include -82.17% in July 30, 2024.

Shareholding & Insider Activity

Repligen Corporation has 56.26 million shares outstanding. The public float is 52.66 million shares, elevated short interest at 9.34% of float. This equals 3.90 million shares. The short ratio is 3.95 days. Institutional investors hold 105.98% of the float. Insiders own 6.4%. DAWES KAREN A holds 91.82 thousand shares, Hunt Anthony has 80.74 thousand shares and Loeillot Olivier has 35.90 thousand shares. Over the past six months, insider transactions show net selling. They sold 14.11 thousand shares across 6 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Repligen generated $638.76M in revenue, or $11.33 per share. Gross margin was 44.50%, operating margin 9.91%, and net profit margin 6.51%. Returns are modest, with ROA at 1.47% and ROE at 2.11%.
On valuation metrics, Repligen trades at a P/E of 4518.63, P/S of 11.11 and P/B of 3.77. The current ratio is 8.36 and quick ratio is 7.14. Operationally, the company’s inventory turnover is 2.41 and cash conversion cycle is 200.38 days. Debt-to-equity is 0.33, supported by a cash flow-to-debt ratio of 0.19.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Repligen posted revenue of $638.76M, down slightly from $801.54M in the prior quarter. Gross profit was $284.25M (margin 44.50%). Operating income was $63.31M (margin 9.9%). Net income was$41.58M (EPS $0.75).
The company ended the quarter with $751.32M in cash and short-term investments, a total debt of $711.80M, and net debt of - $39.52M. Total assets were $2.82B, with equity of $1.97B. Financials further reflected stability, with operating cash flow of $113.92M, free cash flow of $74.93M, and capital expenditures of - $38.99M.

Price Forecast & Outlook

Our AI price prediction model suggests that Repligen Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.86%, with price expected at $124.49 by February 19, 2026, within a range of $120.35 to $128.61 3-Month Outlook: Projected fall of -22.74%, reaching $107.90 by May 06, 2026, with a range of $101.55 to $114.29. 1-Year Outlook: Projected gain of 1.5%, with price at $141.76 by February 05, 2027, within a range of $134.82 to $147.62.

Key Takeaways

Repligen Corporation (NASDAQ:RGEN) shares are flat -0.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Repligen Corporation trading at a premium to the broader market with a P/E of 4518.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $168.40, suggesting 20.58% upside. Our AI forecast model points to short-term weakness (-10.86% over two weeks), a medium-term fall (-22.74% over three months), and a longer-term gain (1.5% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Repligen Corporation (RGEN) stock price?

Repligen Corporation (NASDAQ: RGEN) stock price is $139.66 in the last trading session. During the trading session, RGEN stock reached the peak price of $147.16 while $138.52 was the lowest point it dropped to. The percentage change in RGEN stock occurred in the recent session was -4.41% while the dollar amount for the price change in RGEN stock was - $6.45.

RGEN's industry and sector of operation?

The NASDAQ listed RGEN is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector. Repligen Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RGEN?

Mr. Ralf Kuriyel
Senior Vice President of R&D
Ms. Kimberly Cornwell
Global Head of Legal & Gen. Counsel
Mr. Anthony J. Hunt
Pres, Chief Executive Officer & Director
Mr. Stephen Tingley
Vice President & Head of Global Sales
Mr. Craig Harrison
Senior Vice President of Analytics
Ms. Christine Gebski
Senior Vice President of Filtration & Chromatography
Ms. Rachel Goodrich
Vice President of Marketing
Dr. Jaime M. Humara Ph.D.
Senior Vice President of Marketing
Mr. Jon K. Snodgres
Chief Financial Officer
Mr. Keith Lee Robinson
Chief Information Officer
Neil Whitfield
Vice President of Sales
Ms. Kimberly A. Cornwell
Gen. Counsel
Mr. James R. Bylund
Chief Operating Officer
Mr. Neil Whitfield
Vice President of Sales
Ms. Sondra S. Newman
Global Head of Investor Relations

How RGEN did perform over past 52-week?

RGEN's closing price is 35.63% higher than its 52-week low of $102.97 where as its distance from 52-week high of $175.77 is -20.54%.

How many employees does RGEN have?

Number of RGEN employees currently stands at 1,778.

Link for RGEN official website?

Official Website of RGEN is: https://www.repligen.com

How do I contact RGEN?

RGEN could be contacted at phone 781 250 0111 and can also be accessed through its website. RGEN operates from Building 1, Waltham, MA 02453, United States.

How many shares of RGEN are traded daily?

RGEN stock volume for the day was 765.8K shares. The average number of RGEN shares traded daily for last 3 months was 690.79K.

What is the market cap of RGEN currently?

The market value of RGEN currently stands at $7.86B with its latest stock price at $139.66 and 56.29M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1778
Beta	1.12
Sales or Revenue	$638.76M
5Y Sales Change%	1.56%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Instruments & Supplies

RGEN Company Profile and Key Details

Repligen

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Valuation Metrics

Price Forecast & Outlook

Key Takeaways